Merck & Co. (MRK)
(Delayed Data from NYSE)
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$101.88 USD
-0.44 (-0.43%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $101.93 +0.05 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Merck vs. Pfizer: Which Stock Looks Better Post-Earnings?
by Zacks Equity Research
Pfizer is better positioned than Merck and thus calls for investors' attention post earnings.
Stock Market News for May 03, 2017
by Zacks Equity Research
Benchmarks finished in the green on Tuesday following the release of strong earnings reports
Drug Stock Q1 Earnings Releases on May 4: ZTS, REGN & More
by Zacks Equity Research
Here we have four pharma companies that are set to report first-quarter results on May 4. Let's see how things are shaping up for them.
Pfizer (PFE) Q1 Earnings Beat, Sales Lag, 2017 View Intact
by Zacks Equity Research
Pfizer, Inc. (PFE) reported first-quarter 2017 adjusted earnings per share of 69 cents, which beat the Zacks Consensus Estimate of 67 cents by 3%.
Merck (MRK) Beats on Earnings in Q1, Ups view
by Ekta Bagri
Merck surpassed first-quarter 2017 earnings expectations. The company reported EPS of 88 cents while our consensus called for EPS of 83 cents.
This Week's Most Spectacular Earnings Charts
by Tracey Ryniec
Tracey went through all of the earnings charts to find the best so you don't have to.
6 FDA Events to Watch Out for in May 2017
by Arpita Dutt
Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.
Seattle Genetics (SGEN) Q1 Loss Widens, Sales Top Estimates
by Zacks Equity Research
Seattle Genetics, Inc. (SGEN) reported a loss of 42 cents per share for the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 41 cents and the year-ago loss of 15 cents per share.
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View
by Zacks Equity Research
Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
What's in Store for Merck (MRK) this Earnings Season?
by Zacks Equity Research
Merck & Co., Inc. (MRK) will be reporting first-quarter 2017 earnings on May 2, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.14%.
Bristol-Myers (BMY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Apr 27, before the opening bell.
What's in Store for Agenus (AGEN) this Earnings Season?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report first-quarter 2017 results later this month or early next month.
3 Key Factors to Look Out for in Biogen's Q1 Results
by Arpita Dutt
With Biogen (BIIB) set to report Q1 results tomorrow, here is a look at 3 key factors investors will be focused on apart from earnings and revenue.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Oracle, Merck, Honeywell and Altria
J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.
Zoetis (ZTS) Inks Agreement to Acquire Nexvet Biopharma
by Zacks Equity Research
Zoetis Inc. (ZTS) announced an agreement to buy Nexvet Biopharma plc (NVET) for an aggregate equity valuation of approximately $85 million
Dow 30 Stock Roundup: Microsoft Buys Cloud Tech Firm, Disney's "Beauty and the Beast"
by Swarup Gupta
The index experienced an eventful and holiday shortened week, marked by growing geopolitical tensions.
Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced a collaboration agreement with clinical-stage biopharmaceutical company Apexigen, Inc.
Inovio's Ebola Vaccine Positive in Expanded Phase I Study
by Zacks Equity Research
Inovio Pharmaceuticals, Inc. (INO) recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001.
Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.
Agenus (AGEN) Sharpens Focus on Drug Development Programs
by Zacks Equity Research
We issued an updated report on Agenus Inc. (AGEN) on Apr 4.
5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now
by Zacks Equity Research
Lily carries a Zacks Rank #2 (Buy).
Bristol-Myers (BMY), Incyte to Advance Clinical Program
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
Kite Pharma Completes Filing for CAR-T Therapy with FDA
by Zacks Equity Research
Kite Pharma, Inc. (KITE) announced that it has completed the filing of a rolling submission of the Biologics License Application (BLA) for its lead pipeline candidate, axicabtagene ciloleucel to the FDA.
Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.